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ABSTRACT
The development of short interfering RNA (siRNA),
has provided great hope for therapeutic targeting
of specific genes responsible for patholological
disorders. However, the poor cellular uptake and
bioavailability of siRNA remain a major obstacle to
their clinical development and most strategies that
propose to improve siRNA delivery remain limited
for in vivo applications. In this study, we report a
novel peptide-based approach, MPG-8 an improved
variant of the amphipathic peptide carrier MPG, that
forms nanoparticles with siRNA and promotes their
efficient delivery into primary cell lines and in vivo
upon intra-tumoral injection. Moreover, we show
that functionalization of this carrier with cholesterol
significantly improves tissue distribution and stabil-
ity of siRNA in vivo, thereby enhancing the efficiency
of this technology for systemic administration fol-
lowing intravenous injection without triggering
any non-specific inflammatory response. We have
validated the therapeutic potential of this strategy
for cancer treatment by targeting cyclin B1 in
mouse tumour models, and demonstrate that
tumour growth is compromised. The robustness of
the biological response achieved through this
approach, infers that MPG 8-based technology
holds a strong promise for therapeutic administra-
tion of siRNA.
INTRODUCTION
Although the in vivo delivery of siRNA has been success-
fully achieved thanks to several non-viral delivery systems,
systemic administration of siRNA remains a major chal-
lenge for their therapeutic application (1–5). Over the last
decade, cell-penetrating peptides (CPPs) have been shown
to improve intracellular delivery of various biologically
active molecules into living cells quite eﬃciently (6,7)
and have more recently been applied to siRNA delivery
(8,9). Although conjugation strategies with either
Transportan, Penetratin or Tat certainly improve the
delivery of siRNA into cultured cells, non-covalent stra-
tegies are more appropriate for both in cellulo and in vivo
delivery of siRNA (8,10–17). Short amphipathic cell-
penetrating peptides forming non-covalent, yet stable
complexes with their cargo have been successfully applied
to the delivery of diﬀerent macromolecules into mamma-
lian cells (18,19). In particular, the peptide carrier MPG
eﬃciently delivers siRNA in a fully biologically active
form into a wide variety of cell lines, including embryonic
stem cells (10,11,20). In the present study we describe a
novel strategy which promotes eﬃcient delivery of siRNA
in vivo, using functionalized peptide-based nanoparticular
formulations. We have developed a shorter version of
MPG, MPG-8, that forms stable particles with siRNA,
and that can be functionalized. MPG-8 improves siRNA
delivery ex vivo and in vivo without activating the innate
immune response. We have validated the potential of this
technology by targeting cyclin B1, a non-redundant mito-
tic partner of cyclin-dependent kinase 1 (cdk1) (21) and
report that MPG-mediated administration of siRNA tar-
geting cyclin B1 prevents tumour growth in xenografted
tumour mouse models. Cyclin B1 constitutes a key target
for anti-proliferative strategies and both anti-sense and
siRNA-based-approaches targeting cyclin B1 have been
proposed as an anti-proliferative strategy (22–24). Cyclin
B1 together with Cdk1 kinase, forms the ‘mitosis promot-
ing factor’, whose activity is required for entry into and
progression through mitosis (21). Cdk1 is essential for
mammalian cell division, its knockout is lethal and several
small molecule inhibitors targeting Cdk1 have been
reported to induce arrest in G2 and to reduce tumour
growth (22,24). Likewise, altered expression of cyclin B1
has been reported in numerous cancers
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Peptides and siRNAs
All peptides were synthesized and puriﬁed as previously
described (10,25). Cholesterol conjugation to MPG-8 was
performed at the primary amino group of the N-terminal
residues, then cholesterol-MPG-8 was further puriﬁed by
Reverse Phase-HPLC and analysed by electro-spray ion-
ization mass spectroscopy (25). siRNAs and 50
Alexa
700ﬂuorescently labelled siRNA were synthesized
by Eurogentec according to the following sequences.
Cyc-B1 sense 50-GGCGAAGAUCAACAUGGCATT-30
Cyc-B1 anti-sense 50-UGCCAUGUUGAUCUUCGCCTT-30
Cyc-B3 sense 50-GGUGAAGAUCAGCAUGGCATT-30
Cyc-B3 anti-sense 50-UGCCAUGUCGAUCUUCACCTT-30
GAPDH sense 50-CAUCAUCCCUGCCUCUACUTT-30
GAPDH anti-sense 50-AGUAGAGGCAGGGAUGAUG-30.
Cyc-B1 siRNA targeting cyclin B1, and a derived
siRNA harbouring two mismatches, Cyc-B3, was used
as control. An siRNA targeting GAPDH was used as con-
trol to validate target speciﬁcity and to monitor associated
non-speciﬁc interferon response.
Cell culture and MPG-mediated transfection
Adherent HS68 ﬁbroblasts, HeLa, PC3, MCF-7 and
SCK3-Her2 cell lines [from American Type Culture
Collection (ATCC)] were cultured in Dulbecco’s
Modiﬁed Eagle’s Medium supplemented with 2-mM glu-
tamine, 1% antibiotics (streptomycin 10000mg/ml, peni-
cillin, 10000IU/ml) and 10% (w/v) fetal calf serum (FCS),
at 378C in a humidiﬁed atmosphere containing 5% CO2.
Stock solutions of MPG-8/siRNA and MPG
NLS/siRNA
particles were prepared by complexing 100nM siRNA
with MPG peptides at a molar ratio of 1/20 for 30min
at 378C. Lower concentrations of MPG-carrier/siRNA
(from 20nM to 0.125nM) were obtained by serial dilution
of the stock complexes in PBS, in order to preserve the
same MPG-carrier/siRNA ratio. A total of 150000 cells
seeded in a 35-mm dish the day prior transfection, were
grown to 60% conﬂuence and overlaid with 200ml of pre-
formed complexes, incubated for 3–5min, then 400mlo f
DMEM were added. After a 30-min incubation at 378C,
1ml of fresh DMEM containing 16% FCS was added in
order to reach a ﬁnal FCS concentration of 10%, without
removing the overlay of MPG-8/siRNA complexes. Cells
were returned to the incubator for 24h. Cyclin B1 mRNA
and protein levels were determined 12 and 24h following
transduction, using Quantigen (Panomics Inc.) and west-
ern blotting, respectively. Mouse monoclonal anti-Cyclin
B1 antibodies (SC-245) and rabbit polyclonal anti-Cdk2
antibodies (SC-163) were obtained from Santa Cruz
Biotechnology Inc. Data reported are an average of
three or four distinct experiments.
Mouse tumour models
Athymic female nude mice (6–8 weeks of age) were sub-
cutaneously inoculated into the ﬂank with 1 10
6 PC3 or
SCK-3-HEK2 cells in 100ml PBS. Two to three weeks
after tumour implant, when tumour size reached about
100mm
3, animals were treated by intra-tumoral or intra-
venous injection, every 3 days, with a solution of 0.1ml of
either free Cyc-B1 siRNA (50 or 100mg), control siRNA
Cyc-B3 or Cyc-B1 siRNA (1, 5, 10mg) complexed with
MPG-8 or MPG-8/Chol-MPG-8 at a 1/20 molar ratio.
Formulations containing 15% Chol-MPG-8 were pre-
pared in a stepwise fashion by ﬁrst forming a precomplex
of MPG-8/siRNA at molar ratio of 1/20, followed by
addition of Chol-MPG-8 so as to increase the ratio of
siRNA/carrier to 1/25. Tumour diameter was measured
in two directions at regular intervals using a digital calliper
and tumour volume was calculated as length   width  
height   0.52. Curves show the mean value of tumour
size in a cohort of six animals and neither animal death
nor any sign of toxicity was observed. Experiments were
performed according to national regulations and
approved by the local animal experimentation ethical
committee. The statistical signiﬁcance of the results was
calculated by Student’s t-test and P<0.05 considered to
be statistically signiﬁcant.
Characterization of peptide-based nanoparticles
Mean particle size distribution was determined with a
Coulter N4 Plus (Coulter-Beckman) at 258C for 3min
per measurement and zeta potential was measured with
Zetasizer 4 apparatus (Malvern Ltd,) as previously
described (24).
Cytotoxicity
Toxicity of MPG-8/siRNA complexes was investigated on
HeLa and HS-68 cell lines. A total of 30000 cells seeded in
24-well plate the day prior transfection, were incubated
with increasing concentrations of siRNA complexed with
MPG-8 at a 20/1 molar ratio ranging from 0.1 to 5mM
(100mM MPG-8), for 30min prior to addition of medium
to reach a ﬁnal 10% concentration of FCS. Cytotoxic
response was measured 12h or 24h later by monitoring
the housekeeping gene cyclophilin mRNA level
(Quantigen, Panomic Inc.) and by colorimetric MTT
assay (Sigma, Germany), respectively. For MTT assay,
cell culture medium was removed and replaced with PBS
containing 2.5mg/ml of MTT for 4h. Results correspond
to the average of three separate experiments.
Interferon assay
Interferon response was evaluated on cultured cells
by quantitative RT-PCR monitoring induction of INF-b
and of Interleukin 8 (IL8). HeLa, SCK3-Her2 and MCF7
cells were mock transfected or transfected with MPG-8
MPG-8/Chol-MPG-8/siRNA complexes (100nM) or
poly(I:C) (5mg/ml). After 24h, RNA was isolated using
Trizol (Sigma), and analysed by quantitative RT-PCR,
standardized to GAPDH mRNA. Quantitative PCR was
performed on a Biorad iCycler using primer sequences
for IL8 (forward) 50-GTGCAGTTTTGCCAAGGACT30
and INF-b (forward) 50-CTGGAGCAGCTGAATGGA
AAG-30. In vivo inﬂammatory response was monitored
in the plasma, 6h after injection of either MPG-8/Chol-
MPG-8/siRNA complex, MPG-8, Chol-MPG-8 (0.5mg/
kg) or poly(I:C) (200mg). The level of mouse cytokine
4560 Nucleic Acids Research, 2009, Vol. 37,No. 14tissue tumor necrosis factor (TNF-a). Interferon a
(INF-a) and interleukin 6 (IL6) were quantiﬁed using
sandwich ELISA assay kit (BD Biosciences) according
to the manufacturer’s instructions. The reported results
correspond to the average of two separate experiments
with four animals per group.
In vivo imaging of siRNA biodistribution
In vivo ﬂuorescence imaging was performed as previously
described (26,27). Mice were injected intravenously with
10mg (200ml) of Alexa
700 ﬂuorescently labelled siRNA
either naked or complexed with MPG-8 or MPG-8Chol/
MPG-8 (n=3 animals per group). Anaesthetized mice,
using 2% Isoﬂurane, were illuminated by 663-nm light
emitting diodes equipped with interference ﬁlters and
movies were acquired over the ﬁrst 15 minutes and ﬂuo-
rescence images were taken every hour for 5h and then
after 24h, with a back-thinned CCD cooled camera as
previously described (26,27). At 24h, mice were eutha-
nized and diﬀerent organs were removed for quantiﬁca-
tion of Alexa ﬂuorescence.
RESULTS AND DISCUSSION
Design and evaluation of MPG-8-based nanoparticles
for siRNA delivery
MPG (ac-GALFLGFLGAAGSTMGAWSQPKKKRKV-
Cya) is a primary amphipathic peptide consisting of an
N-terminal hydrophobic motif derived from the fusion
sequence of the HIV protein gp41, a hydrophilic domain
derived from the nuclear localization sequence of SV40
large T antigen, and a short linker which separates these
domains (25). MPG was previously reported to deliver
siRNA into cultured mammalian cells eﬃciently and
to promote potent downregulation of the target at the
protein level, thanks to rapid release of siRNA into the
cytoplasm (10,28). The sequence of MPG was optimized
to improve its interactions with siRNA as well as the sta-
bility of MPG/siRNA complexes. For this purpose, MPG
parent peptide was shortened by six residues: Gly
1, Leu
3,
Ser
13, Ala
17, Glu
20 and Val
27, and the two hydrophobic
Phe
7 and Ala
11 residues were mutated into Trp so as to
favour interactions with both siRNA and lipid phase of
the membrane. We previously demonstrated that the
cysteamide group at the C-terminus of MPG is a prereq-
uisite for its cellular uptake (10), therefore a b-alanine was
added to the N-terminus to allow further functionalization
of the peptide, thereby yielding MPG-8a 21-residue
amphipathic peptide: bAFLGWLGAWGTMGWSPKK
KRK-Cya.
We ﬁrst characterized the eﬃciency of MPG-8 to deliver
siRNA targeting cyclin B1 (Cyc-B1), compared to the
MPG
NLS parent peptide, and found that target silencing
was directly correlated to the ratio, and to the size of
MPG-8/siRNA particles (Figure 1A). An optimal reduc-
tion of cyclin B1 protein level (was achieved for an MPG-
8/siRNA molar ratio of 20/1, corresponding to stable
MPG-8/siRNA particles with a diameter of 120 50nm,
as determined by dynamic light scattering, with a zeta
potential of +16 3 v. At lower ratios, MPG-8/siRNA
particles are unstable and poorly taken up by cells; at
higher ratios, a net increase in the size of particles is asso-
ciated with a reduction of silencing eﬃciency. The parental
peptide MPG
NLS also forms stable particles with siRNA
with an optimal cyclin B1 silencing response (50%) for a
molar ratio of 20/1 and particle size of 260 50nm diam-
eter (Figure 1B). However, the eﬃciency of MPG
NLS
is 2-fold lower than that of MPG-8 at a 20/1 ratio.
Therefore, to ensure optimal biological conditions for
siRNA delivery, throughout the rest of our study, MPG-
8/siRNA particles were systematically prepared at 20/1
ratio. In addition, the toxicity of MPG-8-based
formulations was investigated using either MTT assay or
by monitoring cyclophilin mRNA levels. As reported in
Figure 1C, no toxicity was detected up to a concentration
of 20mM of MPG-8/siRNA particles and only 10–15% of
cell death was observed with 100mM of MPG-8/siRNA
particles.
MPG-8-mediated delivery of siRNA targeting cyclin
B1 induces G2 arrest
Dose–response experiments performed on cultured cells
revealed that MPG-8-mediated delivery of siRNA (Cyc-
B1) induced a robust biological response associated with
downregulation of both cyclin B1 protein and mRNA
levels (Figure 2A and B). An siRNA concentration of
5nM was suﬃcient to reduce cyclin B1 levels by more
than 85% in HeLa cells (Figure 2A) and IC50 of
1.1 0.3nM and 0.9 0.2nM were estimated for down-
regulation of protein levels, and of 0.6 0.1nM and
0.4 0.1nM for mRNA levels, for non-transformed
HS68 ﬁbroblasts (Figure 2B) and HeLa cells (data not
shown), respectively. In comparison, when siRNA were
delivered with MPG
NLS,I C 50 values of 24 5nM and
35 7nM were obtained for downregulation of protein
and mRNA levels, respectively (Figure 2C). That MPG
is 30- to 60-fold less eﬃcient than MPG-8 can be directly
correlated to diﬀerences in stability, solubility and size of
the siRNA/MPG complexes. Reduction of cyclin B1 pro-
tein levels was directly associated with accumulation of
cells with a 4N content, consistent with downregulation
of Cdk1-Cyclin B1 activity, and was optimally obtained
with 2nM siRNA and IC50 values estimated to
0.8 0.2nM and 1.2 0.4nM for HeLa and HS68 cells,
respectively (Figure 2D). In contrast, no eﬀect on cyclin
B1 levels and cell cycle progression was observed with
200nM of an unrelated siRNA (si-GAPDH), or of a
mismatch siRNA harbouring two mutations (Cyc-B3)
complexed with MPG-8 at a 20/1 ratio, or with MPG-8
carrier alone (100mM).
MPG-8-mediated delivery of siRNA targeting cyclin
B1 blocks cancer cell proliferation
The potency of MPG-8/siRNA particles to block cancer
cell proliferation was evaluated using MCF-7, PC3,
SKBr3-HER2 cell lines and compared to the response
observed for HS68 ﬁbroblasts. Cells were treated
on Day 1 with diﬀerent concentrations (0.125–20nM) of
siRNA, MPG-8/siRNA and MPG-8/m-siRNA com-
plexes, and inhibition of cell proliferation was determined
Nucleic Acids Research, 2009,Vol.37, No. 14 4561after 7 days. As reported in Figure 3, subnanomolar con-
centrations of Cyc-B1 siRNA complexed to MPG-8 sig-
niﬁcantly blocked proliferation of the three cancer cell
lines, with IC50 values of 0.6 0.2nM, 0.9 0.3nM and
1.1 0.3nM, for PC3, MCF7 and SKBr3-HER2 cells,
respectively, whereas no eﬀect was observed with control
siRNA or carrier alone. In comparison, the eﬀect of this
treatment on cell proliferation of HS68 ﬁbroblasts was
quite limited, despite eﬃcient downregulation of cyclin
B1 levels (Figure 3D). Although MPG-8/cyclin B1
siRNA compromised proliferation of cancer cells, it only
had a moderate eﬀect on non-cancer cells. These results
are in agreement with previous reports showing that
downregulation of proteins required for the G2/M transi-
tion including Plk1 kinase or cyclin B1 have a limited
eﬀect on non-cancer cells with an active G2/M checkpoint
machinery and do not induce mitotic catastrophes (22,29).
In vivo MPG8-mediated Cyclin B1 siRNA delivery
blocks tumour growth upon topical injection
The potential of MPG-8 to deliver cyclin B1 siRNA in vivo
was ﬁrst evaluated on human prostate carcinoma cell
PC3-xenografted mice (Figure 4A). The eﬀect of local
intra-tumoral administration of MPG-8/siRNA particles
(molar ratio 20/1) on the growth of established
subcutaneous tumours was evaluated. At Day 50,
tumour sizes in the control cohort, injected with PBS
increased by about 3.5-fold. Reduction of tumour
growth by 75% was observed using 1mg (0.05mg/kg) of
siRNA/MPG-8 and tumour growth was completely pre-
vented with 5mg (0.25mg/kg) siRNA/MPG-8 (Figure 4A).
In contrast, intra-tumoral administration of 5mg (0.25mg/
kg) MPG
NLS/siRNA particles did not signiﬁcantly
reduce tumour growth, as only 7–10% of growth curve
deviation was observed in comparison to the saline con-
trol. The poor eﬃciency of MPG
NLS/siRNA is asso-
ciated with low stability of the particles after injection
and the tendency of MPG
NLS/siRNA complexes to pre-
cipitate at the concentration required for in vivo adminis-
tration. At Day 48, we validated that the Cyc-B1 siRNA-
mediated inhibition of tumour growth was directly asso-
ciated with a decrease in the level of cyclin B1 mRNA. As
reported in Figure 4B, the level of cyclin B1 mRNA was
reduced by 58% and 82% with 1 and 5mM of siRNA
formulated with MPG-8, respectively. In contrast, 5mM
MPG
NLS/Cyc-B1siRNA reduced cyclin B1 mRNA by
only 7%, in perfect agreement with the observed variation
in tumour growth (Figure 4B). As a control, we showed
that administration of 50mg (intra-tumoral) or 100mg
(intravenous) naked siRNA or MPG-8 carrier alone had
Figure 1. MPG-8 nanoparticle-mediated delivery of siRNA targeting cyclin B1. Impact of MPG-8 particle size on silencing eﬃciency (A and B):
A ﬁxed concentration of 20nM of siRNA (Cyc-B1) was associated with diﬀerent molar ratios of MPG-8 (A) or MPG (B) ranging from 1/1 to 50/1.
The size of the MPG-8/siRNA or MPG/siRNA particles were measured by light scattering (white bars) and the biological response associated with
siRNA internalization was evaluated in cultured cells by measuring reduction of cyclin B1 protein levels 24h after transfection (grey bars). Toxicity
of MPG-8 particles (C): The toxicity of MPG-8 particles was investigated by MTT assay (grey bars) and by monitoring the level of cyclophilin
mRNA (white bars). HeLa cells were treated with increasing concentrations of MPG-8/siRNA particles ranging from 1 to 100mM and toxicity was
then evaluated 12h (Cyclophilin mRNA) or 24h (MTT) after treatment. Reported data are the average of three separate experiments.
4562 Nucleic Acids Research, 2009, Vol. 37,No. 14no signiﬁcant eﬀect on tumour growth. Moreover, inhibi-
tion of tumour growth was siRNA sequence-speciﬁc
as a cyclin B1 siRNA harbouring two mutations
(Cyc-B3) complexed with MPG-8 and injected into mice
at 0.5mg/kg was unable to inhibit tumour growth
(Figure 4A).
Functionalization of MPG-8 improves in vivo stability
and distribution of MPG-8/siRNA complexes
The stability of drug-carrier formulations in vivo and
in the blood circulation is a major issue for systemic
administration of therapeutics. Despite its demonstrated
potency in cellulo, intravenous injection of MPG-8/siRNA
formulations (0.5mg/kg) only produces an anti-tumoural
response of about 12% (Figures 4A and 7A). Cholesterol
modiﬁcation of siRNA has been reported to enhance their
potency and stability in vivo by maintaining the siRNA
in the circulation for longer periods of time (30,31).
Hence, in order to improve the bioavailability and stabil-
ity of the MPG-8/siRNA particles, thereby rendering
them more suitable for systemic administration, the sur-
face layer of MPG-8/siRNA particles was functionalized
with a cholesterol-moiety at the N- terminus of MPG-8
(Chol-MPG-8), through activation of the N-terminal beta
alanine amino group. Cholesterol-functionalized MPG-8/
siRNA particles were obtained stepwise by complexing
siRNA molecules with MPG-8 at a molar ratio of 20/1,
followed by coating of particles with a second layer of
Chol-MPG-8. The optimal ratio of Chol-MPG-8 required
was determined experimentally, by assessing the ability of
the diﬀerent particles containing between 5 and 50%
Chol-MPG-8 to deliver Cyc-B1 siRNA. Below a ratio of
15% Chol-MPG-8/MPG-8, no signiﬁcant diﬀerence in the
eﬃciency of cyclin B1 silencing, with 85–92% knockdown
of protein or mRNA levels (Figure 5A), nor of the asso-
ciated G2 cell arrest (Figure 5B) were observed. In these
Figure 2. MPG-8-mediated delivery of siRNA targeting cyclin B1 induces G2-arrest. MPG-8 (A and B) and MPG (C) dose–response of Cyclin B1
silencing at the protein and mRNA levels. Stock solutions of MPG-8/siRNA (100nM) or MPG/siRNA (500nM) particles were prepared at a molar
ratio of 1/20, and lower concentrations (from 200nM to 0.125nM) were obtained by serial dilution of the stock solution in PBS. HeLa (A) and HS-
68 (B and C) cells (60% conﬂuency) were overlaid with preformed complexes for 30min, then fresh DMEM supplemented with 10% FCS was added
directly to the cells, which were then returned to the incubator for 24h. Cyclin B1 protein levels were determined by western blotting using Cdk2 as a
control for quantiﬁcation (grey bars). Cyclin B1 mRNA levels were measured 12h after transfection using Quantigen technology (white bars).
Mismatched Cyc-B3 siRNA associated with MPG-8 (200nM) and empty MPG-8 particles (20mM) were used as a control. Dose–response of G2-
arrest associated with Cyclin B1 silencing (D). HeLa (grey bars) and HS68 (white bars) cells were treated with increasing concentrations of MPG-8/
siRNA-Cyc-B1 from 0.25 to 20nM. The cell cycle status was evaluated by FACS analysis. Mismatched Cyc-B3 siRNA (100nM) and GAPDH
siRNA (100nM) associated to MPG-8 as well as to MPG-8 carrier alone (20mM) were used as controls. Results are the means   of four separate
experiments.
Nucleic Acids Research, 2009,Vol.37, No. 14 4563conditions, an IC50 of 1.1 0.2nM was obtained for HS68
cells, similar to the value obtained for non-functionalized
MPG-8 particles. Functionalized-MPG-8/siRNA particles
with 15% of Chol-MPG-8 measure 180 45nm in diam-
eter and are characterized by a zeta potential of 14 2v .
These results indicate that functionalization of the MPG-
8/siRNA particles with 15% of cholesterol alters neither
their physicochemical parameters nor their eﬃciency
to deliver siRNA. We next investigated to what extent
cholesterol functionalization of MPG-8 inﬂuenced the
in vivo bio-distribution of MPG-8/siRNA particles. Mice
were injected intravenously with 10mg of Alexa
700
labelled-siRNA either naked or complexed with MPG-8
or MPG-8Chol/MPG-8. Kinetics of siRNA biodistribu-
tion were measured during the ﬁrst 15min (Figure 6A),
then every hour for 5h (Figure 6B) and ﬂuorescence was
quantiﬁed in the diﬀerent organs 24h after injection
(Figure 6C). Naked siRNA was reported to be rapidly
degraded, with a half-life of a few hours in vivo.
Therefore, as expected, the control experiment performed
with naked siRNA revealed that it rapidly accumulated
in the bladder and in the liver over the ﬁrst hours and
was barely distributed throughout the rest of the body
(Figure 6A, panel 1). In contrast, MPG-8/siRNA
(Figure 6A, panel 2) and MPG-8/MPG-8-Chol/siRNA
(Figure 6A, panel 3) formulations favoured the rapid dis-
tribution of siRNA throughout the body within the ﬁrst
15min following injection, more prominently for the cho-
lesterol functionalized-particles (Figure 6A, panel 2). In
both cases, MPG-8/siRNA (Figure 6B, top panel) and
MPG-8/MPG-8-Chol/siRNA (Figure 6B, bottom panel)
were found to access all tissues and siRNA distribution
was optimal at 5h, accumulating mainly in the lung, liver,
plasma, skin and kidney, adrenal gland and spleen.
Although we cannot exclude that ﬂuorescence is due
to degradation of the siRNA, the fact that siRNA
remains in the plasma and in most of the tissues 24h
after injection (Figure 6C), and also to a certain
extent in the brain, ovary and uterus, conﬁrms the high
stability of MPG-8/siRNA and MPG-8/MPG-8chol/
siRNA particles. No major diﬀerences were obtained
between MPG-8/siRNA and MPG-8/MPG-8chol/
siRNA particles in terms of tissue targeting. However,
cholesterol-functionalization of the particles signiﬁcantly
increased the distribution kinetics of siRNA within
the ﬁrst 15min and maintained a higher level of siRNA
in the plasma even after 24h, in comparison to MPG-8/
siRNA particles, suggesting that it may limit siRNA
clearance, thereby further favouring delivery of siRNA
into the tumour.
Figure 3. Cyclin B1 siRNA-MPG-mediated delivery reduces cancer cell proliferation. PC3 (A), MCF7 (B) SKBR3-HER2 (C) tumour cell lines and
HS-68 (D) were treated on Day 1, with increasing concentrations of MPG-8/siRNA-Cyc-B1 (from 0.125 to 20nM). The concentrations of formulated
siRNA (from 20 to 0.125nM) were obtained by serial dilution as described in Figure 2. The proliferation of cells treated with MPG-8/siRNA (grey
bars) was evaluated on Day 7 and compared to controls including a MPG-8/Cyc-B3 mismatch siRNA (black bars) and MPG-8 carrier alone (white
bars). Results are the average of four independent experiments.
4564 Nucleic Acids Research, 2009, Vol. 37,No. 14Figure 4. MPG-8-mediated Cyclin B1 siRNA delivery inhibits tumour growth upon intra-tumoural injection. (A) Swiss nude mice (a cohort of N=6
animals) were injected subcutaneously with 106 PC3 cells. Thirty days after tumour implant, when tumour size reached 100mm3, animals were
treated by intratumoral injection, every 3 days, with a solution of 0.1ml of either free Cyc-B1 siRNA (100mg) (in blue), control siRNA Cyc-B3
(50mg, in green), Cyc-B1 siRNA (1mg in orange and 5mg in red) complexed with MPG-8 at a 1/20 molar ratio, or Cyc-B1 siRNA (5mg, in purple)
associated with MPG at a 1/20 molar ratio. Curves show the mean value of tumour size. (B) After 48 days, PC3 tumours were removed, and
Cyclin B1 mRNA levels were evaluated by Quantigen and normalized to GAPDH levels.
 P<0.05 versus saline control and
  P<0.01 versus saline
control.
Figure 5. Cholesterol functionalization of MPG-8 does not aﬀect ex-vivo eﬃciency. (A) Cholesterol functionalization of MPG-8-based particles.
Formulations containing variable concentrations of Chol-MPG-8 were obtained by forming a precomplex of MPG-8/siRNA at a molar ratio of 1/20
and then increasing the ratio of siRNA/carrier up to 1/25 with Chol-MPG-8. The impact of the Chol-MPG-8 concentration on particle eﬃciency was
evaluated using 5nM Cyc-B1 siRNA and increasing concentrations of cholesterol-functionalized MPG-8, by measuring Cyclin B1 protein levels by
western blot analysis 24h after transfection (A, top) and mRNA levels by Quantigen assay (A, bottom). mRNA levels were corrected using
cyclophilin level as control (closed circles). (B) Dose–response of G2-arrest associated with Cyclin B1 silencing. HeLa cells were treated with
increasing concentrations of MPG-8/siRNA-Cyc-B1 (grey bars) and of MPG-8/siRNA-Cyc-B1/chol-MPG-8 (white bars) as in Figure 2. The con-
centrations of formulated siRNA (from 20 to 0.25nM) were obtained by serial dilution of the stock solution in PBS. The cell cycle status was
evaluated by FACS analysis. Results are the means   of four separate experiments.
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blocks tumour growth upon systemic injection
In order to analyse if increase in the distribution of siRNA
associated to functionalized-MPG-8 particles directly
aﬀects its potency to inhibit tumour growth, the particles
were used for systemic intravenous administration into
two xenografted tumour mouse models; human prostate
carcinoma (PC3) and human lung cancer (SCK3-HER-2)
injected subcutaneously into the ﬂanks of NCR nude
mice. Five micrograms (0.25mg/kg) and 10mg (0.5mg/
kg) of Cyc-B1 siRNA complexed with MPG/Chol-
MPG-8 at a 20/1 ratio were injected intravenously every
3 days into mice bearing PC3 xenografted tumour and a
signiﬁcant reduction in PC3 tumour size was observed at
Day 50, with 60% and 92% inhibition with 5mg and 10mg
of siRNA, respectively (Figure 7A). The reduction in
tumour size was directly correlated to reduction of cyclin
B1 protein levels, as evaluated by western blotting, by
60% and 80% in animals treated with 5mg and 10mgo f
siRNA complexed to MPG-8/Chol-MPG-8, respectively
(Figure 7A, insert). These results together with the lack
of anti-tumoural activity of the mismatch siRNA/MPG/
Chol-MPG-8 (10mg) or of MPG-8/Chol-MPG-8 carrier
alone, underscores the robustness and speciﬁcity of the
biological response associated with systemic delivery
of cyclin B1 siRNA. MPG/Cyc-B1-siRNA/Chol-MPG8
particles were next evaluated on human lung cancer
cells (SCK3-HER-2) xenografted mice. After 20 days,
reduction of tumour growth of 70% was achieved with
10mg (0.5mg/kg) of Cyc-B1-siRNA/MPG-8/Chol-MPG-
8 (data not shown). Further analysis of the mice that
received (10mg) of Cyc-B1-siRNA/MPG-8/Chol-MPG-8
in comparison to control (PBS) or mice injected
with Cyc-B1-siRNA/MPG-8 or Cyc-B3 siRNA/MPG-8/
Chol-MPG-8, demonstrated a signiﬁcant increase in
survival at Day 40, with 70% of survival, instead of
20% with cholesterol free MPG-8 formulation
(Figure 7C). Moreover, 50% of survival was observed
after 100 days through injection of cholesterol-functiona-
lized particles every 3 days for 20 days, then every 10 days
(10mg) (Figure 7B), demonstrating the long-term eﬃciency
of this approach. In contrast, no signiﬁcant eﬀect was
observed with non-functionalized MPG-8-particles,
suggesting that cholesterol increases the biodistribution
Figure 6. In vivo biodistribution of MPG-8 and cholesterol functionalization of MPG-8. Mice were injected intravenously with 10mg (200ml) of
Alexa
700 ﬂuorescently labelled siRNA either naked (A, 1) or complexed with MPG-8 (A, 2) or MPG-8Chol/MPG-8 (A, 3). Anaesthetized mice were
illuminated by 663nm light emitting diodes equipped with interference ﬁlters and ﬂuorescence images and real-time kinetics of biodistribution were
acquired during the ﬁrst 15min with time of exposures ranging from 100 to 200ms/image (A), then every hour for 5h and after 24h (B). The level of
ﬂuorescently labelled siRNA in the diﬀerent organs was quantiﬁed 24h after administration (C). Results are the average of three animals per group.
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plasma.
The potential induction of inﬂammatory cytokine and
interferon responses by siRNA has been reported as a
major limitation to their therapeutic application (32–34).
As interferon response has been recently reported for
covalent CPP-siRNA formulations (34), we investigated
the ability of MPG-8 and MPG-8/Chol formulations to
induce innate immune response in cultured HeLa, MCF7
and SCK3-HER-2 cells, by monitoring expression of INF-
b and of IL8 by quantitative RT-PCR (Figure 7C), and
in vivo by quantifying the level of IFN-a, TNF-a and IL6
in the plasma (Figure 7D). As reported in Figure 7C, none
of the formulations triggered activation of interferon
response, the level of expression of INF-b and IL8 being
similar to those of the negative control, in contrast to
poly(I:C) (positive control) which induced 1.0–1.7-fold
gene expression depending on the gene and the cell line.
Similarly no increase in cytokine level, in comparison to
saline solution, was observed in the plasma, 6h after
Figure 7. Systemic administration of MPG-8/MPG-8chol/cyclin B1 siRNA blocks tumour growth in vivo. (A) Inhibition of PC3 tumour growth
upon intravenous injection. Swiss nude nice (a cohort of N=6 animals) were injected subcutaneously with 106 PC3 cells and tumour analysis was
performed as described in Figure 4A. Animals were treated by intravenous tail vein injection, every 3 days, with a solution of 0.1ml of either PBS
(black), free Cyc-B1 siRNA (100mg:blue), Cyc-B1 siRNA (10mg) complexed with MPG-8 (purple), control siRNA Cyc-B3 (100mg: green) or Cyc-B1
siRNA (5mg: orange and 10mg: red) complexed with MPG-8/chol-MPG-8 at a 1/20 molar ratio. Curves show the mean value of tumour size in a
group of six animals. After 48 days, PC3 tumours were removed, and Cyclin B1 protein levels were evaluated by western blotting (insert) in control
(lane a), 5mg siRNA (lane b) and 10mg siRNA (lane c) complexed with MPG-8/chol-MPG-8at a 1/20 molar ratio.
 P<0.05 versus saline control
and
  P<0.01 versus saline control. (B) Inhibition of SK-BR3 HER2 tumour growth upon intravenous injection. Swiss nude mice (a cohort of
N=10 animals) were injected subcutaneously with 106 SK-BR3 HER2 cells. Ten days after tumour implant, when tumour size reached 100mm3,
animals were treated by intravenous tail vein injection, every 3 days from D10 to D30, then every 10 days, with a solution of 0.1ml of either PBS
(green), Cyc-B1 siRNA (10mg) complexed with MPG-8 (blue) and Cyc-B3 (100mg: orange) Cyc-B1 siRNA (10mg: red) complexed with MPG-8/Chol-
MPG-8. Control mice treated by intravenous tail vein injection of (10mg) Cyc-B1 siRNA complexed with MPG-8/Chol-MPG-8 (black)
 P < 0.05
versus saline control and
  P < 0.01 versus saline control. (C) Expression of IFN response genes: expression of INF-b and IL8 relative to GAPDH
was analysed by quantitative RT–PCR. HeLa, MCF7 and SCK3-Her2 cells were treated with MPG-8 carrier alone (white) (20mM), 20nM of Cyc-B1
siRNA associated with MPG-8 (black) or MPG-8/Chol-MPG8 (light grey) particles. Poly(I:C) was used as a positive control to induce interferon
response (grey). (D) MPG-8 formulation does not induce interferon response in vivo. MPG-8/siRNA, MPG-8/MPG-8-Chol/siRNA (0.5mg/kg),
and MPG-8 carrier were intravenously injected into mice and IL-6 (grey), TNF-a (white) and IFN-g (black) induction were measured in the serum
6h after injection by sandwich ELISA and expressed as pg/ml. (P versus saline controls
 <0.05,
  <0.01) each value is the mean of three separate
experiments.
Nucleic Acids Research, 2009,Vol.37, No. 14 4567injection of any formulation (Figure 7D). Interferon
response of siRNA and formulations has been associated
to the binding to Toll Like Receptors within the endosome
(33). As such, the lack of activation of interferon response
with MPG-8 is in perfect agreement with an endosomal-
independent uptake pathway (10).
CONCLUSIONS
Despite the potential of siRNA in vitro and ex vivo, their
systemic delivery remains a major obstacle to therapeutic
administration (4). Several reports using polycationic for-
mulations (35), protamine-antibodies (36,37) and peptides
(12,17) have largely proven that non-covalent strategies
are very suitable approaches for siRNA delivery, as they
improve the stability of siRNA in biological ﬂuids,
thereby increasing their overall potency. In the present
work, we have developed a potent strategy to deliver
siRNA in vivo based on an improved variant of the pri-
mary amphipathic peptide carrier MPG, MPG-8, which
forms stable, yet non-covalent nanoparticles with siRNA,
ensuring its eﬃcient delivery in vivo. We provide a proof –
of concept that MPG-8 mediates eﬃcient delivery of
low eﬀective concentrations of siRNA (0.5mg/kg)
in vivo. Moreover, we demonstrate that siRNA-targeting
of cyclin B1 compromises tumour cell proliferation and
tumour growth in a xenografted tumour mouse model.
The high stability of MPG-8-based particles, together
with the slow release of the siRNA within cells, allows the
use of low concentrations of siRNA, thereby limiting
side eﬀects whilst ensuring long-term response associated
with siRNA delivery. MPG-8-based nanoparticles can be
functionalized, and we have shown that an additional
layer of cholesterol-functionalized-MPG-8 at the surface
of MPG-8/siRNA particles is suﬃcient to stabilize these
formulations in biological ﬂuids, thereby enhancing the
biological response associated with the siRNA delivered
upon systemic injection. Likewise, functionalization of
MPG-8 with other chemical groups or biological moieties
could be applied to generate formulations to target speciﬁc
cell types or tissues will be of a major interest for future
development. Taken together, these ﬁndings provide new
perspectives for the speciﬁc targeting and treatment of
tumours, and the marked anti-tumoural eﬀect achieved
with the MPG-8-based nanoparticle system, with very
low concentrations of siRNA and the lack of induction
of innate immunoresponse, infers that it constitutes a
promising technology for systemic administration of
siRNA in a therapeutic context.
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